Examkin

Soru

Zorluk: KolayPulmonary and Critical Care

A 62-year-old man is recovering in the intensive care unit on day 3 of an admission for acute hypoxemic respiratory failure secondary to severe community-acquired pneumonia. Upon admission, he required endotracheal intubation and mechanical ventilation. Empiric therapy was initiated with intravenous vancomycin and cefepime. Today, his clinical condition has markedly improved; he is afebrile, his oxygenation has stabilized, and he is being evaluated for extubation. Sputum cultures obtained via endotracheal aspirate on admission are now growing Streptococcus pneumoniae. Susceptibility testing demonstrates that the organism is highly sensitive to penicillin, ceftriaxone, and levofloxacin, but resistant to macrolides. Blood cultures from admission have shown no growth. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

  1. Discontinue vancomycin and cefepime, and start intravenous ceftriaxoneCevap
  2. B
    Continue vancomycin and cefepime for a total of 7 days
  3. C
    Discontinue vancomycin and continue intravenous cefepime
  4. D
    Discontinue vancomycin and cefepime, and start intravenous meropenem
  5. E
    Add intravenous levofloxacin to the current antibiotic regimen

Cevap

Discontinue vancomycin and cefepime, and start intravenous ceftriaxone.
The correct action is to de-escalate the antibiotic regimen to a targeted, narrower-spectrum agent based on the culture results. The patient has a confirmed Streptococcus pneumoniae infection that is sensitive to ceftriaxone. Continuing broad-spectrum agents like vancomycin (which targets MRSA) and cefepime (which targets Pseudomonas and other resistant Gram-negative rods) is unnecessary and violates the core principles of antimicrobial stewardship.

Adım Adım Çözüm

1
Identify the patient's current clinical status and microbiological data.
The patient is improving clinically, and sputum cultures have isolated Streptococcus pneumoniae that is sensitive to ceftriaxone.
Clinical improvement and definitive culture results dictate the next steps in antibiotic management.
2
Evaluate the current antibiotic regimen against the culture results.
The patient is currently on vancomycin (covering MRSA) and cefepime (covering Pseudomonas and other Gram-negatives), which are overly broad for susceptible S. pneumoniae.
Empiric broad-spectrum therapy must be reassessed once a specific pathogen is identified.
3
Select the optimal targeted therapy.
Ceftriaxone provides excellent, targeted coverage for this isolate of S. pneumoniae while minimizing collateral damage to the patient's microbiome.
Antibiotic stewardship principles require narrowing therapy to the most specific, effective, and safe agent available once susceptibilities are known.

Anahtar Kavram

In patients started on empiric broad-spectrum antibiotics for severe infections, therapy should be de-escalated to targeted, narrow-spectrum agents as soon as culture and susceptibility results become available to minimize resistance and toxicity.
Tahmini Süre:45s
Bu soruyu puanla

Konular

Pulmonary and Critical Care

Bu konudan daha fazla soru